GD2 target antigen and CAR T cells: does it take more than 2 to tango?

Over the past decade, chimeric antigen receptor (CAR) T cells have emerged as a breakthrough cancer therapy in selected hematological malignancies. Translating the success of this therapy to solid tumors is challenging. Here, we discuss strategies potentially useful to increase the CAR T-cell efficacy in this clinical indication.